B cell therapies in antineutrophil cytoplasmic antibody-associated vasculitis: why measure B cells and immunoglobulins?

Banham, Gemma; Sagmeister, Michael; Harper, Lorraine

DOI:

<https://doi.org/10.1093/ndt/gfaa196>

License:

Unspecified

Document Version

Peer reviewed version

Citation for published version (Harvard):

Banham, G, Sagmeister, M & Harper, L 2020, 'B cell therapies in antineutrophil cytoplasmic antibody-associated vasculitis: why measure B cells and immunoglobulins?', *Nephrology, Dialysis, Transplantation*.
<https://doi.org/10.1093/ndt/gfaa196>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Standard licence used by journal -can forward documentation on request

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

B cell therapies in ANCA associated vasculitis: why measure B cells and immunoglobulins?

Dr Gemma D Banham, Dr Michael S Sagmeister, Prof. Lorraine Harper

Institute of Clinical Sciences, University of Birmingham

Correspondence to: Gemma D. Banham; E-mail: gemma.banham@nhs.net

NOTICE: following is the author's peer reviewed version of a work that has been accepted for publication in Nephrology Dialysis Transplantation. Changes resulting from the publishing process, such as editing, corrections, structural formatting, and other quality control mechanisms are not reflected in this document. Changes have been made to this work since it was submitted for publication.

A definitive version was subsequently published in Nephrology Dialysis Transplantation, 05

November 2020

<https://doi.org/10.1093/ndt/gfaa196>

Introduction

B cell targeted therapies are becoming more widely used to treat inflammatory kidney disease. However, even within specific diseases, there is significant heterogeneity in disease phenotype and response to therapy. Antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is an example of a disease in which use of B cell targeted therapies are increasingly common. Rituximab, a murine chimeric monoclonal antibody depleting B cells expressing CD20, is an alternative induction immunosuppression agent to cyclophosphamide and offers an alternative to azathioprine as maintenance immunosuppression (1). We will focus on experience of rituximab use in AAV to illustrate the role of monitoring differential white cell counts and immunoglobulins.

Why measure B cell counts?

Modern treatments for AAV are effective at inducing disease remission in most patients. A greater challenge lies in maintaining ongoing remission and limiting progressive chronic kidney disease, whilst avoiding treatment-related morbidity and mortality, particularly from infections. B cell depleting therapy can have variable pharmacodynamic effects, with significant variability in timing of B cell reconstitution. B cell reconstitution following rituximab is delayed in AAV compared to use in other rheumatic diseases (2).

The optimum duration and dosing frequency of rituximab in AAV remains unknown. Fixed dose rituximab appears to be a safe and effective maintenance regimen in AAV. B cell return within 12 months of the last rituximab infusion is a risk factor for further disease relapse (3), however individualised approaches to rituximab dosing based on biomarkers have so far failed to show improved outcomes. Rituximab administration tailored to CD19 B cell reappearance or rising ANCA titre was associated with non-statistically significant trends towards increased relapses but reduced rituximab usage in AAV, compared to a fixed dose regimen (17.3% versus 9.9%; $P=0.22$)(4).

Differential white cell counts may not reflect all sources of autoreactive B cells. High sensitivity flow cytometry reveals minimal residual autoimmunity below the detection of standard assays (5), with evidence for ANCA-memory B cells detectable following rituximab therapy (6). Furthermore, B cell depletion in the peripheral blood does not correlate with depletion of tissue resident cells (7). Belimumab is an antibody targeting B cell-activating factor (BAFF; also known as BLyS), a critical B cell survival factor associated with autoimmunity. In a randomised controlled trial belimumab did not improve remission rates in AAV compared to placebo, however it was noted that relapses only occurred in belimumab treated patients who had received cyclophosphamide induction with those induced with rituximab remaining in remission (8). The COMBIVAS study is testing the hypothesis that belimumab in combination with rituximab, may negate the rise in serum BAFF levels seen following B cell depletion, promote migration of tissue resident memory B cells into the circulation exposing them to rituximab mediated depletion and modulate the phenotype of reconstituting B cells (1).

Differential white cell counts may detect late onset neutropenia, a recognised complication of rituximab therapy, occurring in around 10% of those treated with repeated doses of rituximab in AAV (9). Neutropenia appears to be associated with more prolonged B cell depletion, occurring at a median time of 102 days (range 40–362 days) following rituximab dosing (10). Treatment with granulocyte colony-stimulating factor should be considered when neutropenia is symptomatic. Discontinuation of rituximab is not required.

Why measure immunoglobulins?

Antibodies are an important component of the adaptive immune response. Although B cell targeted therapies seem to preferentially target pathogenic antibodies they can cause generalised hypogammaglobinaemia. Hypogammaglobinaemia predisposes to recurrent and severe infections.

Among 243 patients who received rituximab for autoimmune rheumatic disease (AIRD), IgG hypogammaglobinaemia was present in 26% at the time of rituximab initiation and 56% during follow up; 26% of cases in this cohort were classified as moderate or severe (IgG <5 g/L), with half of these showing spontaneous improvement (11). Mature plasma cells, the source of most circulating IgG, do not express CD20 and are not depleted by rituximab. Early immunoglobulin decline after rituximab is often transient, with underlying disease and prior or concomitant immunosuppression therapy believed to contribute. Late onset immunoglobulin decline can be sustained, with a median time to immunoglobulin nadir of 35 months (range 1-70 months) (12). This is considered to reflect prolonged depletion of plasma cell precursors leading to reduced replenishment of mature plasma cells.

Low immunoglobulin levels prior to initiation of rituximab predict subsequent sustained hypogammaglobinaemia and are associated with increased risk of infection post rituximab, but should not be viewed as a contraindication to therapy. Concomitant or prior immunosuppression, especially cyclophosphamide may have a synergistic effect. Recent consensus recommendations suggest checking immunoglobulin levels prior to commencement of B cell targeted therapy and repeating every 6-12 months up to a minimum of one year after stopping treatment, with longer monitoring in selected patients (13).

Patients with sustained hypogammaglobinaemia with severe, persistent, unusual or recurrent infections, who fail to make antibody responses to unconjugated polysaccharide vaccines may benefit from immunoglobulin replacement therapy following a trial of antibiotic prophylaxis (13). Retrospective case reports suggest requirement for immunoglobulin replacement in 4.2% to 21% of patients treated with rituximab for AIRD (11, 12). Discontinuation of rituximab on the grounds of worsening symptomatic hypogammaglobinaemia must be weighed against the benefits of controlling underlying disease and availability of alternative immunosuppressant therapy.

Conclusions

Measurement of the phenotype of reconstituting B cells in a research setting may allow us to better understand the role of B cells in pathogenesis, identify risk factors for treatment failure and limit treatment-related adverse events. This may guide optimal duration and frequency of B cell depleting treatment and open the door for more patient-tailored approaches providing disease suppression to patients at high risk of disease relapse whilst limiting potential treatment toxicity in those at low risk. Greater understanding of the relevance of findings and how they impact on clinical outcomes is required before this becomes part of standard of care. Vigilance for symptomatic late onset neutropenia and prompt treatment of associated infections is important but there is no evidence to suggest monitoring for asymptomatic neutropenia. Monitoring of immunoglobulin levels is useful to limit treatment associated infectious complications and guide immunoglobulin replacement therapy.

Figure 1: Treatment with rituximab induces variable duration of peripheral B cell depletion and optimal frequency and duration of dosing is unclear. Minimal residual autoimmunity below the threshold of detection or present within tissue niches may be treatment-resistant and drive recurrent disease. Combination therapies may better target autoimmune B cells. Belimumab, an anti BAFF monoclonal antibody, is hypothesised to promote migration of tissue resident B cells into the periphery. Long term depletion of plasma cell precursors may cause hypogammaglobinaemia resulting in infectious complications due to loss of protective immunity. Prophylactic antibiotics and Intravenous immunoglobulin (IVIG) replacement are recommended in line with guidelines for secondary immunodeficiency

1. McClure M, Gopaluni S, Jayne D, Jones R. B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. *Nat Rev Rheumatol*. 2018;14(10):580-91.
2. Thiel J, Rizzi M, Engesser M, Dufner AK, Troilo A, Lorenzetti R, et al. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. *Arthritis Res Ther*. 2017;19(1):101.
3. Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. *Rheumatology (Oxford)*. 2015;54(7):1153-60.
4. Charles P, Terrier B, Perrodeau E, Cohen P, Faguer S, Huart A, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). *Ann Rheum Dis*. 2018;77(8):1143-9.
5. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. *Arthritis Rheum*. 2008;58(10):2993-9.

6. van Dam LS, Oskam JM, Kamerling S, Arends EJ, Brendewold E, van Dongen J, et al. Minimal Residual Autoimmunity After Rituximab in ANCA-Associated Vasculitis Patients. Poster presentation FR-PO824, Kidney Week. 2019.
7. Ramwadhoebe TH, van Baarsen LGM, Boumans MJH, Bruijnen STG, Safy M, Berger FH, et al. Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2019;58(6):1075-85.
8. Jayne D, Blockmans D, Luqmani R, Moiseev S, Ji B, Green Y, et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. *Arthritis & rheumatology (Hoboken, NJ)*. 2019;71(6):952-63.
9. Pendergraft WF, 3rd, Cortazar FB, Wenger J, Murphy AP, Rhee EP, Laliberte KA, et al. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. *Clin J Am Soc Nephrol*. 2014;9(4):736-44.
10. Tesfa D, Ajeganova S, Hagglund H, Sander B, Fadeel B, Hafstrom I, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. *Arthritis Rheum*. 2011;63(8):2209-14.
11. Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. *Journal of autoimmunity*. 2015;57:60-5.
12. Wijetilleka S, Mukhtyar C, Jayne D, Ala A, Bright P, Chinoy H, et al. Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review. *Autoimmunity reviews*. 2019;18(5):535-41.
13. Wijetilleka S, Jayne DR, Mukhtyar C, Ala A, Bright PD, Chinoy H, et al. Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. *Rheumatology (Oxford)*. 2019;58(5):889-96.